Q61.19 Other polycystic kidney, infantile type
The ICD-10-CM code for Other polycystic kidney, infantile type is Q61.19 (FY2026). It is a billable, claim-ready diagnosis code.
Classification
- Section
- Q60-Q64: Congenital malformations of the urinary system (Q60-Q64)
- Category Q61
- 14 codes (11 billable)
- FY2026 Status
- Stable since FY2024
Also Known As
ICD-10-CM Alphabetic Index entries that lead to Q61.19:
- Polycystic (disease) › kidney › infantile type NEC
- Cystic › kidney (congenital) › infantile type NEC
- Nephritis, nephritic (albuminuric) (azotemic) (congenital) (disseminated) (epithelial) (familial) (focal) (granulomatous) (hemorrhagic) (infantile) (nonsuppurative, excretory) (uremic) › polycystic › infantile type NEC
- Polycystic (disease) › degeneration, kidney › autosomal recessive (infantile type) NEC
- Polycystic (disease) › kidney › autosomal recessive (childhood type) NEC
- Nephritis, nephritic (albuminuric) (azotemic) (congenital) (disseminated) (epithelial) (familial) (focal) (granulomatous) (hemorrhagic) (infantile) (nonsuppurative, excretory) (uremic) › polycystic › childhood type NEC
- Disease, diseased › kidney (functional) (pelvis) › polycystic › childhood type NEC
- Degeneration, degenerative › kidney › polycystic › infantile type (autosomal recessive) NEC
U.S. Hospital Utilization
- An estimated 775 U.S. inpatient stays in 2023 included Q61.19 among the documented diagnoses.
- 65 stays listed it as the principal diagnosis.
Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.
Official Coding Guidelines
POA indicator for congenital conditions/anomalies and Q00-Q99 exceptionCongenital conditions and anomalies Assign “Y” for congenital conditions and anomalies except for categories Q00- Q99, Congenital anomalies, which are on the exempt list. Congenital conditions are always considered present on admission.
Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026